HDAC9 and lip and oral cavity carcinoma: The unmet need for an effective treatment to prevent progression of OED to oral cancer, the risk-reduction effect demonstrated in the Kang study and the underlying plausible epigenetic mechanisms underpin the need for a clinical trial using VPA as an HDAC inhibitor in the chemoprevention of oral cancer in individuals with high-risk OED.